Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.

Krieter P, Chiang CN, Gyaw S, Skolnick P, Snyder R.

Drug Metab Dispos. 2019 Jul;47(7):690-698. doi: 10.1124/dmd.118.085977. Epub 2019 Apr 16.

2.

Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.

Krieter P, Gyaw S, Crystal R, Skolnick P.

J Pharmacol Exp Ther. 2019 Nov;371(2):409-415. doi: 10.1124/jpet.118.256115. Epub 2019 Apr 2.

PMID:
30940694
3.

Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose.

Krieter P, Gyaw S, Chiang CN, Crystal R, Skolnick P.

J Clin Pharmacol. 2019 Jul;59(7):947-957. doi: 10.1002/jcph.1384. Epub 2019 Jan 30.

4.

On the front lines of the opioid epidemic: Rescue by naloxone.

Skolnick P.

Eur J Pharmacol. 2018 Sep 15;835:147-153. doi: 10.1016/j.ejphar.2018.08.004. Epub 2018 Aug 7.

5.

A Survey of Payer Perspectives on Cannabis Use Disorder.

Kiselica AM, Duhig A, Montoya I, Skolnick P, Floyd J, Byars C.

Subst Use Misuse. 2018 Nov 10;53(13):2257-2264. doi: 10.1080/10826084.2018.1473432. Epub 2018 Jun 21.

PMID:
29927691
6.

Medication development in opioid addiction: Meaningful clinical end points.

Volkow ND, Woodcock J, Compton WM, Throckmorton DC, Skolnick P, Hertz S, Wargo EM.

Sci Transl Med. 2018 Mar 28;10(434). pii: eaan2595. doi: 10.1126/scitranslmed.aan2595. Review.

PMID:
29593105
7.

The development of glutamate-based antidepressants is taking longer than expected.

Garay R, Zarate CA Jr, Cavero I, Kim YK, Charpeaud T, Skolnick P.

Drug Discov Today. 2018 Oct;23(10):1689-1692. doi: 10.1016/j.drudis.2018.02.006. Epub 2018 Mar 1. No abstract available.

8.

The Opioid Epidemic: Crisis and Solutions.

Skolnick P.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:143-159. doi: 10.1146/annurev-pharmtox-010617-052534. Epub 2017 Oct 2. Review.

PMID:
28968188
9.

From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.

Acri JB, Cross AJ, Skolnick P.

Psychopharmacology (Berl). 2017 May;234(9-10):1347-1355. doi: 10.1007/s00213-016-4501-9. Epub 2016 Dec 20. Review.

PMID:
27995279
10.

Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic.

Skolnick P, Volkow ND.

Neuron. 2016 Oct 19;92(2):294-297. doi: 10.1016/j.neuron.2016.09.051.

11.

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.

Bespalov A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer MA, Prinssen E, Ballard T, Macleod M.

Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.88. Epub 2016 Jun 17. No abstract available.

PMID:
27312728
12.

Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.

Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R, Keegan F, Aker J, Beck M, Harris J.

J Clin Pharmacol. 2016 Oct;56(10):1243-53. doi: 10.1002/jcph.759. Epub 2016 Jun 10.

PMID:
27145977
13.

Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, Dunn K, Dworkin RH, Fertig J, Gewandter J, Moeller FG, Ramey T, Ryan M, Silverman K, Strain EC.

Drug Alcohol Depend. 2016 Jan 1;158:1-7. doi: 10.1016/j.drugalcdep.2015.11.004. Epub 2015 Nov 21. Review.

14.

Mitigating the Effects of Nonadherence in Clinical Trials.

Shiovitz TM, Bain EE, McCann DJ, Skolnick P, Laughren T, Hanina A, Burch D.

J Clin Pharmacol. 2016 Sep;56(9):1151-64. doi: 10.1002/jcph.689. Epub 2016 Jan 22.

15.

Biologic Approaches to Treat Substance-Use Disorders.

Skolnick P.

Trends Pharmacol Sci. 2015 Oct;36(10):628-635. doi: 10.1016/j.tips.2015.07.002. Review.

16.

Synopsis of Expert Opinions and Conclusions.

Skolnick P, White D, Acri JB.

CNS Neurol Disord Drug Targets. 2015;14(6):773-6. No abstract available.

PMID:
26073938
17.

Editorial: Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of Constrained Resources?

Skolnick P, White D, Acri JB.

CNS Neurol Disord Drug Targets. 2015;14(6):691. No abstract available.

PMID:
26073937
18.

Trends in opioid analgesic abuse and mortality in the United States.

McCann DJ, Skolnick P.

N Engl J Med. 2015 Apr 16;372(16):1572-3. doi: 10.1056/NEJMc1501822. No abstract available.

PMID:
25875269
19.

Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.

Skolnick P, Kos T, Czekaj J, Popik P.

Acta Neuropsychiatr. 2015 Aug;27(4):228-34. doi: 10.1017/neu.2015.14. Epub 2015 Apr 10.

PMID:
25858023
20.

Harry L June.

Skolnick P.

Neuropsychopharmacology. 2014 Dec;39(13):3135. doi: 10.1038/npp.2014.254. No abstract available.

21.

1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.

Popik P, Holuj M, Nikiforuk A, Kos T, Trullas R, Skolnick P.

Psychopharmacology (Berl). 2015 Mar;232(6):1025-38. doi: 10.1007/s00213-014-3738-4. Epub 2014 Sep 27.

22.

Translational potential of naloxone and naltrexone as TLR4 antagonists.

Skolnick P, Davis H, Arnelle D, Deaver D.

Trends Pharmacol Sci. 2014 Sep;35(9):431-2. doi: 10.1016/j.tips.2014.06.008. Epub 2014 Aug 7. No abstract available.

PMID:
25109569
23.

Therapeutic doses of buspirone block D3 receptors in the living primate brain.

Kim SW, Fowler JS, Skolnick P, Muench L, Kang Y, Shea C, Logan J, Kim D, Carter P, King P, Alexoff D, Volkow ND.

Int J Neuropsychopharmacol. 2014 Aug;17(8):1257-67. doi: 10.1017/S1461145714000194. Epub 2014 Mar 28. Erratum in: Int J Neuropsychopharmacol. 2014 Aug;17(8):1354.

PMID:
24679922
24.

Glutamate-based antidepressants: preclinical psychopharmacology.

Pilc A, Wierońska JM, Skolnick P.

Biol Psychiatry. 2013 Jun 15;73(12):1125-32. doi: 10.1016/j.biopsych.2013.01.021. Epub 2013 Feb 28. Review.

PMID:
23453290
25.

Response to W. Sieghart.

Skolnick P.

Trends Pharmacol Sci. 2013 Mar;34(3):146. doi: 10.1016/j.tips.2013.01.007. Epub 2013 Feb 4. No abstract available.

PMID:
23384390
26.

Addiction therapeutics: obstacles and opportunities.

Skolnick P, Volkow ND.

Biol Psychiatry. 2012 Dec 1;72(11):890-1. doi: 10.1016/j.biopsych.2012.08.004. No abstract available.

27.

Anxioselective anxiolytics: on a quest for the Holy Grail.

Skolnick P.

Trends Pharmacol Sci. 2012 Nov;33(11):611-20. doi: 10.1016/j.tips.2012.08.003. Epub 2012 Sep 14. Review.

28.

Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.

Warnock KT, Yang AR, Yi HS, June HL Jr, Kelly T, Basile AS, Skolnick P, June HL.

Pharmacol Biochem Behav. 2012 Nov;103(1):111-8.

29.

Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Bergman J, Roof RA, Furman CA, Conroy JL, Mello NK, Sibley DR, Skolnick P.

Int J Neuropsychopharmacol. 2013 Mar;16(2):445-58. doi: 10.1017/S1461145712000661. Epub 2012 Jul 25.

30.

Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

Newman AH, Blaylock BL, Nader MA, Bergman J, Sibley DR, Skolnick P.

Biochem Pharmacol. 2012 Oct 1;84(7):882-90. doi: 10.1016/j.bcp.2012.06.023. Epub 2012 Jul 3. Review.

31.

Editorial: magic bullets and arrows: biologic approaches to treat substance use disorders.

Skolnick P, Volkow ND.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):864. No abstract available.

32.

New medications for substance use disorders: challenges and opportunities.

Volkow ND, Skolnick P.

Neuropsychopharmacology. 2012 Jan;37(1):290-2. doi: 10.1038/npp.2011.84.

33.

Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.

Yang AR, Yi HS, Warnock KT, Mamczarz J, June HL Jr, Mallick N, Krieter PA, Tonelli L, Skolnick P, Basile AS, June HL Sr.

Alcohol Clin Exp Res. 2012 May;36(5):863-73. doi: 10.1111/j.1530-0277.2011.01671.x. Epub 2011 Dec 7.

34.

Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M.

J Psychiatr Res. 2012 Jan;46(1):64-71. doi: 10.1016/j.jpsychires.2011.09.003. Epub 2011 Sep 16.

35.

The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.

Lindholm JS, Autio H, Vesa L, Antila H, Lindemann L, Hoener MC, Skolnick P, Rantamäki T, Castrén E.

Neuropharmacology. 2012 Jan;62(1):391-7. doi: 10.1016/j.neuropharm.2011.08.015. Epub 2011 Aug 16.

PMID:
21867718
36.

The secrets of a successful clinical trial: compliance, compliance, and compliance.

Czobor P, Skolnick P.

Mol Interv. 2011 Apr;11(2):107-10. doi: 10.1124/mi.11.2.8. No abstract available.

37.

A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder.

Czobor P, Skolnick P, Beer B, Lippa A.

CNS Neurosci Ther. 2010 Apr;16(2):63-75. doi: 10.1111/j.1755-5949.2009.00109.x. Epub 2009 Dec 22.

38.

Glutamate-based antidepressants: 20 years on.

Skolnick P, Popik P, Trullas R.

Trends Pharmacol Sci. 2009 Nov;30(11):563-9. doi: 10.1016/j.tips.2009.09.002. Review.

PMID:
19837463
39.

Preclinical evaluation of the abuse potential of the analgesic bicifadine.

Nicholson KL, Balster RL, Golembiowska K, Kowalska M, Tizzano JP, Skolnick P, Basile AS.

J Pharmacol Exp Ther. 2009 Jul;330(1):236-48. doi: 10.1124/jpet.109.150540. Epub 2009 Apr 8.

40.

Pharmacological Properties of DOV 315,090, an ocinaplon metabolite.

Berezhnoy D, Gravielle MC, Downing S, Kostakis E, Basile AS, Skolnick P, Gibbs TT, Farb DH.

BMC Pharmacol. 2008 Jun 13;8:11. doi: 10.1186/1471-2210-8-11.

41.

AMPA receptors: a target for novel antidepressants?

Skolnick P.

Biol Psychiatry. 2008 Feb 15;63(4):347-8. doi: 10.1016/j.biopsych.2007.10.011. No abstract available.

PMID:
18237615
42.

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.

Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS.

J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18.

PMID:
18089843
43.

Triple uptake inhibitors: therapeutic potential in depression and beyond.

Chen Z, Skolnick P.

Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77. Review.

PMID:
17714023
44.

Triple reuptake inhibitors ("broad spectrum" antidepressants).

Skolnick P, Basile AS.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9. Review.

PMID:
17430151
45.

Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.

Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, Nikiforuk A, Krawczyk M, Nowak G, Krieter PA, Lippa AS, Skolnick P, Koustova E.

J Pharmacol Exp Ther. 2007 Jun;321(3):1208-25. Epub 2007 Feb 26.

PMID:
17325229
46.

The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors.

Popik P, Kostakis E, Krawczyk M, Nowak G, Szewczyk B, Krieter P, Chen Z, Russek SJ, Gibbs TT, Farb DH, Skolnick P, Lippa AS, Basile AS.

J Pharmacol Exp Ther. 2006 Dec;319(3):1244-52. Epub 2006 Sep 13.

PMID:
16971504
47.

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.

Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A.

CNS Drug Rev. 2006 Summer;12(2):123-34. Review.

48.

Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):857-73. Epub 2006 Apr 25.

PMID:
16636898
49.

Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

Lippa A, Czobor P, Stark J, Beer B, Kostakis E, Gravielle M, Bandyopadhyay S, Russek SJ, Gibbs TT, Farb DH, Skolnick P.

Proc Natl Acad Sci U S A. 2005 May 17;102(20):7380-5. Epub 2005 May 3.

50.

DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.

Beer B, Stark J, Krieter P, Czobor P, Beer G, Lippa A, Skolnick P.

J Clin Pharmacol. 2004 Dec;44(12):1360-7.

PMID:
15545306

Supplemental Content

Loading ...
Support Center